186 related articles for article (PubMed ID: 35249990)
1. Renal Cell Carcinoma With Fibromyomatous Stroma-The Whole Story.
Shah RB
Adv Anat Pathol; 2022 May; 29(3):168-177. PubMed ID: 35249990
[TBL] [Abstract][Full Text] [Related]
2. "Renal Cell Carcinoma With Leiomyomatous Stroma" Harbor Somatic Mutations of TSC1, TSC2, MTOR, and/or ELOC (TCEB1): Clinicopathologic and Molecular Characterization of 18 Sporadic Tumors Supports a Distinct Entity.
Shah RB; Stohr BA; Tu ZJ; Gao Y; Przybycin CG; Nguyen J; Cox RM; Rashid-Kolvear F; Weindel MD; Farkas DH; Trpkov K; McKenney JK
Am J Surg Pathol; 2020 May; 44(5):571-581. PubMed ID: 31850909
[TBL] [Abstract][Full Text] [Related]
3. Positive GPNMB Immunostaining Differentiates Renal Cell Carcinoma With Fibromyomatous Stroma Associated With TSC1/2/MTOR Alterations From Others.
Li H; Argani P; Halper-Stromberg E; Lotan TL; Merino MJ; Reuter VE; Matoso A
Am J Surg Pathol; 2023 Nov; 47(11):1267-1273. PubMed ID: 37661807
[TBL] [Abstract][Full Text] [Related]
4. TSC/MTOR mutated renal cell carcinoma with leiomyomatous stroma is a distinct entity: a comprehensive study of 12 cases.
Tjota MY; Sharma A; Wanjari P; Fitzpatrick C; Segal J; Antic T
Hum Pathol; 2023 Apr; 134():124-133. PubMed ID: 36592877
[TBL] [Abstract][Full Text] [Related]
5. Mutated ASXL1 upregulates mTOR expression in renal cell carcinoma with fibromyomatous stroma.
Liu Y; Zhou L; Xu H; Gu Y; Dong L; Yang X; Wang C
Virchows Arch; 2023 Dec; ():. PubMed ID: 38102390
[TBL] [Abstract][Full Text] [Related]
6. Biallelic ELOC-Inactivated Renal Cell Carcinoma: Molecular Features Supporting Classification as a Distinct Entity.
Batavia AA; Rutishauser D; Sobottka B; Schraml P; Beerenwinkel N; Moch H
Mod Pathol; 2023 Aug; 36(8):100194. PubMed ID: 37088333
[TBL] [Abstract][Full Text] [Related]
7. New insights in the new WHO classification of adult renal tumors.
Hes O; Michalová K; Pivovarčíková K
Cesk Patol; 2022; 67(4):187-191. PubMed ID: 36513503
[TBL] [Abstract][Full Text] [Related]
8. Renal cell carcinoma with angioleiomyoma-like stroma and clear cell papillary renal cell carcinoma: exploring SDHB protein immunohistochemistry and the relationship to tuberous sclerosis complex.
Williamson SR; Hornick JL; Eble JN; Gupta NS; Rogers CG; True L; Grignon DJ; Cheng L
Hum Pathol; 2018 May; 75():10-15. PubMed ID: 29180251
[TBL] [Abstract][Full Text] [Related]
9. Analysis of clinicopathological and molecular features of ELOC(TCEB1)-mutant renal cell carcinoma.
Wang Y; Zhao P; Wang L; Wang J; Ji X; Li Y; Shi H; Li Y; Zhang W; Jiang Y
Pathol Res Pract; 2022 Jul; 235():153960. PubMed ID: 35653922
[TBL] [Abstract][Full Text] [Related]
10. Renal Cell Carcinoma in Tuberous Sclerosis Complex.
Henske EP; Cornejo KM; Wu CL
Genes (Basel); 2021 Oct; 12(10):. PubMed ID: 34680979
[TBL] [Abstract][Full Text] [Related]
11. TSC/MTOR-mutated eosinophilic renal tumors are a distinct entity that is CK7+/CK20-/vimentin-: a validation study.
Tjota MY; Wanjari P; Segal J; Antic T
Hum Pathol; 2021 Sep; 115():84-95. PubMed ID: 33352195
[TBL] [Abstract][Full Text] [Related]
12. Somatic Mutations of TSC2 or MTOR Characterize a Morphologically Distinct Subset of Sporadic Renal Cell Carcinoma With Eosinophilic and Vacuolated Cytoplasm.
Chen YB; Mirsadraei L; Jayakumaran G; Al-Ahmadie HA; Fine SW; Gopalan A; Sirintrapun SJ; Tickoo SK; Reuter VE
Am J Surg Pathol; 2019 Jan; 43(1):121-131. PubMed ID: 30303819
[TBL] [Abstract][Full Text] [Related]
13. Tuberous sclerosis-associated renal cell carcinoma: a clinicopathologic study of 57 separate carcinomas in 18 patients.
Guo J; Tretiakova MS; Troxell ML; Osunkoya AO; Fadare O; Sangoi AR; Shen SS; Lopez-Beltran A; Mehra R; Heider A; Higgins JP; Harik LR; Leroy X; Gill AJ; Trpkov K; Campbell SC; Przybycin C; Magi-Galluzzi C; McKenney JK
Am J Surg Pathol; 2014 Nov; 38(11):1457-67. PubMed ID: 25093518
[TBL] [Abstract][Full Text] [Related]
14. Renal Cell Carcinoma Associated With TSC/MTOR Genomic Alterations: An Update on its Expanding Spectrum and an Approach to Clinicopathologic Work-up.
Shah RB; Mehra R
Adv Anat Pathol; 2024 Mar; 31(2):105-117. PubMed ID: 37899532
[TBL] [Abstract][Full Text] [Related]
15.
Zhang KJ; Qu Z; Pszenica E; Hafron JM; Zhang PL; Brown RE
Ann Clin Lab Sci; 2023 Jan; 53(1):3-13. PubMed ID: 36889765
[TBL] [Abstract][Full Text] [Related]
16. Renal cell carcinoma with leiomyomatous stroma in tuberous sclerosis complex: a distinct entity.
Gournay M; Dugay F; Belaud-Rotureau MA; Peyronnet B; Mathieu R; Verhoest G; Bensalah K; Odent S; Denizeau P; Vigneau C; Morini A; Rioux-Leclercq N; Kammerer-Jacquet SF
Virchows Arch; 2021 Apr; 478(4):793-799. PubMed ID: 32845354
[TBL] [Abstract][Full Text] [Related]
17. Eosinophilic Renal Cell Tumors With a TSC and MTOR Gene Mutations Are Morphologically and Immunohistochemically Heterogenous: Clinicopathologic and Molecular Study.
Tjota M; Chen H; Parilla M; Wanjari P; Segal J; Antic T
Am J Surg Pathol; 2020 Jul; 44(7):943-954. PubMed ID: 32091432
[TBL] [Abstract][Full Text] [Related]
18. Genetic Underpinnings of Renal Cell Carcinoma With Leiomyomatous Stroma.
Parilla M; Alikhan M; Al-Kawaaz M; Patil S; Kadri S; Ritterhouse LL; Segal J; Fitzpatrick C; Antic T
Am J Surg Pathol; 2019 Aug; 43(8):1135-1144. PubMed ID: 30986793
[TBL] [Abstract][Full Text] [Related]
19. Somatic Bi-allelic Loss of TSC Genes in Eosinophilic Solid and Cystic Renal Cell Carcinoma.
Mehra R; Vats P; Cao X; Su F; Lee ND; Lonigro R; Premkumar K; Trpkov K; McKenney JK; Dhanasekaran SM; Chinnaiyan AM
Eur Urol; 2018 Oct; 74(4):483-486. PubMed ID: 29941307
[TBL] [Abstract][Full Text] [Related]
20. TSC/MTOR -associated Eosinophilic Renal Tumors Exhibit a Heterogeneous Clinicopathologic Spectrum : A Targeted Next-generation Sequencing and Gene Expression Profiling Study.
Xia QY; Wang XT; Zhao M; He HY; Fang R; Ye SB; Li R; Wang X; Zhang RS; Lu ZF; Ma HH; Wang ZY; Rao Q
Am J Surg Pathol; 2022 Nov; 46(11):1562-1576. PubMed ID: 35980750
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
